The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer

The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer

As an antibody-drug conjugate (ADC), disitamab vedotin (RC48) is a promising treatment targeting ERBB2 for locally advanced and metastatic bladder cancer (BLCA). However, the subtype heterogeneity of muscle-invasive bladder cancer (MIBC) often leads to different therapeutic outcomes. In our study, w...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingxian Li, Kun Shan, Wei Huang, Qiang Su, Yuanjiong Qi, Zhihong Zhang, Jianqiang Zhu, E. Du
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
RC48-ADC
MIBC
artesunate
molecular subtypes
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1432586/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items